AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
UK High Court Upholds Alvotech's Right to Manufacture AVT06, a Biosimilar to Eylea
ByAinvest
Monday, Nov 10, 2025 4:02 am ET1min read
Alvotech has won a UK High Court case against Regeneron and Bayer, paving the way for the manufacture and market entry of AVT06, a biosimilar to Eylea. The court rejected the injunction request, allowing Alvotech to continue manufacturing and storing AVT06 in the UK for distribution in the UK, EEA, and other countries after the expiry date for Supplementary Protection Certificates for Eylea. The decision supports commercial launches of Alvotech's biosimilar in Europe and other regions after November 23, 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet